Novartis Ag (NVS) FCF Margin Growth (5y) (2014 - 2026)
Powered by 
Analysis
Novartis Ag (NVS) FCF Margin Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 846.00 |
| Mar 31, 2026 | 1,153.00 |
| Dec 31, 2025 | 2,842.00 |
| Sep 30, 2025 | 2,177.00 |
| Jun 30, 2025 | 1,277.00 |
| Mar 31, 2025 | 695.00 |
| Dec 31, 2024 | -1,483.00 |
| Sep 30, 2024 | 1,111.00 |
| Jun 30, 2024 | 1,222.00 |
| Mar 31, 2024 | -308.00 |
| Dec 31, 2023 | 1,819.00 |
| Sep 30, 2023 | 852.00 |
| Jun 30, 2023 | -373.00 |
| Mar 31, 2023 | 357.00 |
| Dec 31, 2022 | 2,321.00 |
| Sep 30, 2022 | 1,514.00 |
| Jun 30, 2022 | -58.00 |
| Mar 31, 2022 | -549.00 |
| Dec 31, 2021 | -994.00 |
| Sep 30, 2021 | 1,019.00 |